Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.54 |
| ▸ | CPN1 | P15169 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9283742 | 0.83 | MAOA (0.55) | CPN1CPB2MAOAMAOBCYP19A1 | |
| SCHEMBL288636 | 0.82 | SLC7A5 (0.67) | GRIA2ALPIPKMPTGS1XIAP | |
| SCHEMBL29475725 | 0.82 | SLC7A5 (0.67) | GRIA2ALPIPKMPTGS1XIAP | |
| SCHEMBL1104873 | 0.82 | MAOB (0.48) | KDM6BCPN1CPB2MAOAMAOB | |
| SCHEMBL288729 | 0.82 | SLC7A5 (0.67) | GRIA2ALPIPKMPTGS1XIAP | |
| SCHEMBL385392 | 0.82 | SLC7A5 (0.67) | GRIA2ALPIPKMPTGS1XIAP | |
| SCHEMBL1067198 | 0.81 | PLA2G10 (0.50) | CPN1CPB2MAOAMAOBSLC7A5 | |
| SCHEMBL14923017 | 0.81 | MAOA (0.47) | CPN1CPB2MAOAMAOBSLC1A1 | |
| SCHEMBL2865019 | 0.80 | KDM6B (0.61) | KDM6BGRIA2PKMNOS2 | |
| SCHEMBL2862796 | 0.80 | KDM6B (0.61) | KDM6BGRIA2PKMNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| CN-104284655-A | Methods of treating lactose intolerance | NOGRA PHARMA LTD | 2015-01-14 | — | — | CN | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| EP-1910270-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-05-08 | — | — | EP | claimed |
| US-8153693-B2 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | claimed |
| EP-2222291-B1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | GIULIANI INT LTD (IE) | 2012-03-21 | — | — | EP | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| CN-102020577-A | Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field | GIULIANI INT LTD | 2011-04-20 | — | — | CN | claimed |
| CN-101969943-A | Compounds for the selective treatment of the intestinal immunoinflammatory component of celiac disease | GIULIANI INT LTD | 2011-02-09 | — | — | CN | claimed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | claimed |
| EP-2222291-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | claimed |
| WO-2009080828-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | claimed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | claimed |
| CN-101243039-A | PPAR receptor and EGF receptor specific compounds and salts thereof and their use in the medical field | GIULIANI INT LTD (IE) | 2008-08-13 | — | — | CN | claimed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| EP-3628317-A1 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2020-04-01 | — | — | EP | disclosed |
| EP-2811993-B1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LTD (IE) | 2019-10-09 | — | — | EP | disclosed |
| EP-2811993-B1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LTD (IE) | 2019-10-09 | — | — | EP | disclosed |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2018-07-10 | — | — | US | disclosed |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2018-07-10 | — | — | US | disclosed |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2018-07-10 | — | — | US | disclosed |
| EP-2895160-B1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2018-05-30 | — | — | EP | disclosed |
| EP-2895160-B1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2018-05-30 | — | — | EP | disclosed |
| US-9913817-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2018-03-13 | — | — | US | disclosed |
| US-9913817-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2018-03-13 | — | — | US | disclosed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2017-11-02 | — | — | US | disclosed |
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2017-11-02 | — | — | US | disclosed |
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2017-11-02 | — | — | US | disclosed |
| US-9682923-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-9682923-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2017-03-02 | — | — | US | disclosed |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2017-03-02 | — | — | US | disclosed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | disclosed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | disclosed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | disclosed |
| US-9345680-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2016-05-24 | — | — | US | disclosed |
| US-9345680-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2016-05-24 | — | — | US | disclosed |
| US-9345680-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2016-05-24 | — | — | US | disclosed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | NOGRA PHARMA LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | NOGRA PHARMA LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-9133099-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2015-09-15 | — | — | US | disclosed |
| US-9133099-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2015-09-15 | — | — | US | disclosed |
| US-9133099-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2015-09-15 | — | — | US | disclosed |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LIMITED (IE) | 2015-09-10 | — | — | US | disclosed |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LIMITED (IE) | 2015-09-10 | — | — | US | disclosed |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LIMITED (IE) | 2015-09-10 | — | — | US | disclosed |
| CN-104837486-A | Methods of treating hair related conditions | NOGRA PHARMA LTD | 2015-08-12 | — | — | CN | disclosed |
| EP-2897603-A1 | METHODS OF INHIBITING HAIR GROWTH | Nogra Pharma Limited (IE) | 2015-07-29 | — | — | EP | disclosed |
| CN-104736149-A | Methods of inhibiting hair growth | NOGRA PHARMA LTD | 2015-06-24 | — | — | CN | disclosed |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | disclosed |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
| CN-104284655-A | Methods of treating lactose intolerance | NOGRA PHARMA LTD | 2015-01-14 | — | — | CN | disclosed |
| CN-104254327-A | Methods of treating fibrosis | NOGRA PHARMA LTD | 2014-12-31 | — | — | CN | disclosed |
| EP-2811993-A2 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2014-12-17 | — | — | EP | disclosed |
| US-8710100-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2014-04-29 | — | — | US | disclosed |
| US-8710100-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2014-04-29 | — | — | US | disclosed |
| US-8710100-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2014-04-29 | — | — | US | disclosed |
| WO-2014041140-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LIMITED (IE) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014041141-A1 | METHODS OF INHIBITING HAIR GROWTH | NOGRA PHARMA LIMITED (IE) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014041141-A1 | METHODS OF INHIBITING HAIR GROWTH | NOGRA PHARMA LIMITED (IE) | 2014-03-20 | — | — | WO | disclosed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013117744-A9 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013117744-A2 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-08-15 | — | — | WO | disclosed |
| US-8501806-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2013-08-06 | — | — | US | disclosed |
| US-8501806-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2013-08-06 | — | — | US | disclosed |
| EP-1910270-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-05-08 | — | — | EP | disclosed |
| EP-1910270-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-05-08 | — | — | EP | disclosed |
| CN-101243039-B | PPAR receptor and EGF receptor specific compounds and salts thereof and their use in the medical field | GIULIANI INT LTD | 2013-04-03 | — | — | CN | disclosed |
| CN-102020577-B | Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field | GIULIANI INT LTD | 2013-03-13 | — | — | CN | disclosed |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2013-01-03 | — | — | US | disclosed |
| CN-102641279-A | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | GIULIANI INT LTD | 2012-08-22 | — | — | CN | disclosed |
| US-20120157417-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | BARONI SERGIO (IT) | 2012-06-21 | — | — | US | disclosed |
| US-20120157417-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | BARONI SERGIO (IT) | 2012-06-21 | — | — | US | disclosed |
| US-20120157417-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | BARONI SERGIO (IT) | 2012-06-21 | — | — | US | disclosed |
| US-8153841-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-8153693-B2 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-8153693-B2 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-8153693-B2 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-8153841-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-8153841-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| EP-2222291-B1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | GIULIANI INT LTD (IE) | 2012-03-21 | — | — | EP | disclosed |
| CN-102264360-A | Methods of preventing or reducing colon carcinogenesis | — | 2011-11-30 | — | — | CN | disclosed |
| CN-102264361-A | Method for preventing or reducing carcinogenesis or oxidative stress | — | 2011-11-30 | — | — | CN | disclosed |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| EP-2355810-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | Giuliani International Limited (IE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2355809-A1 | METHODS FOR PREVENTING OR REDUCING COLON CARCINOGENESIS | Giuliani International Limited (IE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| CN-102020577-A | Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field | GIULIANI INT LTD | 2011-04-20 | — | — | CN | disclosed |
| CN-101969943-A | Compounds for the selective treatment of the intestinal immunoinflammatory component of celiac disease | GIULIANI INT LTD | 2011-02-09 | — | — | CN | disclosed |
| EP-2279733-A2 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | Giuliani International Limited (IE) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279733-A2 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | Giuliani International Limited (IE) | 2011-02-02 | — | — | EP | disclosed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | disclosed |
| EP-2222291-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010063472-A1 | METHODS FOR PREVENTING OR REDUCING COLON CARCINOGENESIS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063472-A1 | METHODS FOR PREVENTING OR REDUCING COLON CARCINOGENESIS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063470-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | disclosed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009080828-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080828-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | disclosed |
| CN-101243039-A | PPAR receptor and EGF receptor specific compounds and salts thereof and their use in the medical field | GIULIANI INT LTD (IE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| CN-1325385-A | Gastrin and cholecystokinin receptor ligands | BLACK JAMES FOUNDATION (GB) | 2001-12-05 | — | — | CN | disclosed |
| CN-1325385-A | Gastrin and cholecystokinin receptor ligands | BLACK JAMES FOUNDATION (GB) | 2001-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (23 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | EGFR, ERBB3, FGFR3 | KDM6B 3799/4885CPN1 3318/4885CPB2 2395/4885 |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | KDM6B 1217/4885CPN1 3258/4885CPB2 1102/4885 |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | KDM6B 1245/4885CPN1 2301/4885CPB2 451/4885 |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | KDM6B 3799/4885CPN1 3318/4885CPB2 2395/4885 |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | SI, FABP2, NFKBIA | KDM6B 2084/4885CPN1 150/4885CPB2 65/4885 |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KDM6B 3799/4885CPN1 3318/4885CPB2 2395/4885 |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | KDM6B 1245/4885CPN1 2301/4885CPB2 451/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | KDM6B 1245/4885CPN1 2301/4885CPB2 451/4885 |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KDM6B 3799/4885CPN1 3318/4885CPB2 2395/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | KDM6B 1217/4885CPN1 3258/4885CPB2 1102/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | KDM6B 1307/4885CPN1 2341/4885CPB2 2006/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | KDM6B 3076/4885CPN1 696/4885CPB2 700/4885 |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | KDM6B 1307/4885CPN1 2341/4885CPB2 2006/4885 |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | APC, GSTK1, GSTA1 | KDM6B 1497/4885CPN1 3029/4885CPB2 1741/4885 |
| US-20120157417-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | SI, FABP2, NFKBIA | KDM6B 2003/4885CPN1 145/4885CPB2 71/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KDM6B 3799/4885CPN1 3318/4885CPB2 2395/4885 |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KDM6B 3798/4885CPN1 3370/4885CPB2 2354/4885 |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | DCX, HDGF, MKI67 | KDM6B 373/4885CPN1 2102/4885CPB2 2213/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | KDM6B 1245/4885CPN1 2301/4885CPB2 451/4885 |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KDM6B 3799/4885CPN1 3318/4885CPB2 2395/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | KDM6B 3076/4885CPN1 696/4885CPB2 700/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | KDM6B 4841/4885CPN1 2091/4885CPB2 1744/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | KDM6B 1245/4885CPN1 2301/4885CPB2 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.